Gå direkt till huvudinnehållet

Klimakteriet

Senast uppdaterad: Senast reviderad:
Sakkunnig:
Definition:
Klimakteriet omfattar perioden före och efter menopaus (den sista menstruationen).
Förekomst:
De flesta kvinnor i Sverige får menopaus vid 40–58 års ålder, medianåldern är 52 år.
Symtom:
Typiska symtom är blödningsrubbningar, värmevallningar, svettningar (framförallt nattliga), sömnstörningar och eventuellt psykiska symtom. Så småningom symtom till följd av atrofi av urogenitala slemhinnor.
Kliniska fynd:
Kliniska fynd kan vara atrofiska urogenitala slemhinnor.
Diagnostik:
Tilläggsundersökningar är vanligen inte nödvändiga. Hormonanalyser kan ibland vara till hjälp.
Behandling:
Eventuellt hormonbehandling.
  1. Kaunitz AM, Manson JE. Management of Menopausal Symptoms. Obstet Gynecol. 2015. pmid:26348174 PubMed  
  2. Svensk förening för obstetrik och gynekologi (SFOG). ARG-rapport Hormonbehandling i klimakteriet. 2010 www.sfog.se  
  3. Vujovic S, Brincat M, Erel T, Gambacciani M, Lambrinoudaki I, Moen MH, Schenck-Gustafsson K, Tremollieres F, Rozenberg S, Rees M; European Menopause and Andropause Society.EMAS position statement: Managing women with premature ovarian failure. Maturitas 2010;67:91-3. PubMed  
  4. Duffy OK, Iversen L, Hannaford PC. Factors associated with reporting classic menopausal symptoms differ. Climacteric 2013; 16: 240-51. pmid:22992029 PubMed  
  5. Santoro N, Epperson CN, Mathews SB. Menopausal Symptoms and Their Management. Endocrinol Metab Clin North Am. 2015 Sep;44(3):497-515
  6. Menopausal hormonbehandling (MHT). Endokrin-ARG - Bakgrundsdokument MHT, antagna 210121 www.sfog.se  
  7. Livsmedelsverket. Nordiska Näringsrekommendationer 2012. www.livsmedelsverket.se  
  8. Pinkerton JAV, Aguirre FS, Blake J et al. The 2017 hormone therapy position statement of the North American Menopause Society. Menopause. 2017 Jul 1;24(7):728-753. PMID: 28650869 PubMed  
  9. Kemmler W, Häberle L, von Stengel S. Effects of exercise on fracture reduction in older adults : A systematic review and meta-analysis. Osteoporos Int. 2013 Jul:1937-50. pmid: 23306820 PubMed  
  10. Daley A, Thomas A, Roalfe A, et al. The effectiveness of exercise as treatment for vasomotor menopausal symptoms: randomised controlled trial. BJOG. 2014 PMID: 25516405 PubMed  
  11. Daley A, Stokes-Lampard H, Thomas A, MacArthur C. Exercise for vasomotor menopausal symptoms. Cochrane Database of Systematic Reviews 2014, Issue 11. Art. No.: CD006108. pmid: 25431132 PubMed  
  12. Läkemedel vid klimakteriesymtom, menopausal hormonbehandling (MHT) - behandlingsrekommendation. Läkemedelsverket 2022. via.tt.se  
  13. Corbelli J, Shaikh N, Wessel C, et al. Low-dose transdermal estradiol for vasomotor symptoms: a systematic review. Menopause. 2015 Jan;22(1):114-21. PubMed  
  14. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013; 310: 1353-68. pmid: 24084921 PubMed  
  15. Furness S, Roberts H, Marjoribanks J, et al. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev 2012 Aug 15;8 pmid: 22895916 PubMed  
  16. Formoso G, Perrone E, Maltoni S, et al. Short-term and long-term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev. 2016 Oct 12;10:CD008536. Epub ahead of print. pmid: 27733017 PubMed  
  17. Davis SR, Moreau M, Kroll R et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med 2008; 359: 2005-17. PMID: 18987368 PubMed  
  18. Elraiyah T, Sonbol MB, Wang Z et al. Clinical review: The benefits and harms of systemic testosterone therapy in postmenopausal women with normal adrenal function: a systematic review and meta-analysis. J Clin Endocrinol Metab 2014; 99(10): 3543-50. pmid:25279572 PubMed  
  19. Löfqviist H. Bioidentiska hormoner bör kunna förskrivas. Läkartidningen 08/2018 lakartidningen.se  
  20. Gaudard AIS, Silva de Souza S et al. Bioidentical hormones for women with vasomotor symptoms. Cochrane Database of Systematic Reviews 2016, Issue 8. Art. No.: CD010407 pmid: 27479272 PubMed  
  21. Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes. Systematic review and meta-analysis. JAMA 2006; 295: 2057-71. pmid: 16670414 PubMed  
  22. Shams T, Firwana B, Habib F, et al. SSRIs for Hot Flashes: A systematic review and meta-analysis of randomized trials. J Gen Intern Med. 2013 Jul 26 PMID: 23888328 PubMed  
  23. Archer DF, Seidman L, Constantine GDS, et al. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol 2009; 200: 172. PubMed  
  24. Sarri G, Pedder H, Dias S, Guo Y1, Lumsden MA. Vasomotor symptoms resulting from natural menopause: a systematic review and network meta-analysis of treatment effects from the National Institute of Health and Care Excellence guideline on menopause. BJOG 2017. pmid:28276200 PubMed  
  25. Caraci F, Crupi R, Drago F, Spina E. Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract. Curr Drug Metab 2011;12:570-7. PMID: 21395523 PubMed  
  26. Gupta J, Kai J, Middleton L, et al. Levonorgestrel intrauterine system versus medical therapy for menorrhagia. N Engl J Med 2013; 368: 128-37. pmid: 23301731 PubMed  
  27. O'Connor KA, Ferrel R, Brindle E, et al. Progesterone and ovulation across stages of the transition to menopause. Menopause 2009; 16: 1178-87. pmid: 19568209 PubMed  
  28. Wu JP, Pickle S. Extended use of the intrauterine device: a literature review and recommendations for clinical practice. Contraception 2014; 89(6): 495-503. pmid:24679478 PubMed  
  29. Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews 2017, Issue 1. Art. No.: CD004143. PMID: 28093732 PubMed  
  30. Lokkegaard E, Nielsen LH, Keiding N. Risk of Stroke With Various Types of Menopausal Hormone Therapies: A National Cohort Study. Stroke. 2017; 48: 2266-9. PMID: 28626058 PubMed  
  31. Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016 Aug 31;(8):CD001500..CD001500.pub3.pmid: 27577677 PubMed  
  32. Holmberg L, Iversen OE, Rudenstam CM, et al. HABITS Study Group. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 2008;100:475-82. PubMed  
  33. Canonico M, Plu-Bureau G, Lowe GDO, Scarabin P-Y. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis . BMJ 2008; 336: 1227-31. PubMed  
  34. Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality. JAMA 2017; 318: 927-38. PMID: 28898378. PubMed  
  35. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease. The Women's Health Initiative. Arch Intern Med 2006; 166(3): 357-365. PubMed  
  36. Grady D, Herrington D, Bittner V, et al, for the HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 2002; 288: 49-57. PubMed  
  37. Chlebowski RT, Anderson GL, Aragaki AK et al. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials. JAMA. 2020 Jul 28;324(4):369-380. PMID: 32721007 PubMed  
  38. Nelson HD, Walker M, Zakher B, Mitchell J. Menopausal hormone therapy for the primary prevention of chronic conditions: A systematic review to update the U.S. Preventive Services Task Force recommendations. Ann Intern Med 2012; 157: 1-10. PMID: 22786830 PubMed  
  39. Renoux C, Dellàniello S, Garbe E, et al. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010; 340: c2519. pmid: 20525678 PubMed  
  40. Schierbeck LL, Rejnmark L, Tofteng CL et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012. pmid:23048011 PubMed  
  41. Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Eng J Med 2016; 374: 1221-31. pmid: 27028912 PubMed  
  42. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons US Preventive Services Task Force Recommendation Statement. JAMA 2022; 328: 1740-1746. PMID: 36318127 PubMed  
  43. Boardman HMP, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database of Systematic Reviews 2015; 3: CD002229. pmid:25754617 PubMed  
  44. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 2019; 364: k4810. doi:10.1136/bmj.k4810 DOI  
  45. Manson JE, Chlebowski RT, Stefanick ML et al. The Women’s Health Initiative Hormone Therapy Trials: Update and Overview of Health Outcomes During the Intervention and Post-Stopping Phases. JAMA 2013; 310: 1353-68. pmid:24084921 PubMed  
  46. Simon JA, Laliberté F, Duh MS, et al. Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy. Menopause 2016. pmid: 26953655 PubMed  
  47. Lethaby A, Hogervorst E, Richards M, Yesufu A, Yaffe K. Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD003122. DOI: 10.1002/14651858.CD003122.pub2 DOI  
  48. Savolainen-Peltonen H, Rahkola-Soisalo P, Hoti F et al. Use of postmenopausal hormone therapy and risk of Alzheimer's disease in Finland: nationwide case-control study. BMJ. 2019 Mar 6;364:l665. PMID: 30842086 PubMed  
  49. Vincent A, Barton DL, Mandrekar JN, et al. Acupuncture for hot flashes: randomized, sham-controlled clinical study. Menopause 2007; 14: 45-52. PubMed  
  50. Ee C, Xue C, Chondros P, et al. Acupuncture for menopausal hot flashes: A randomized trial. Ann Intern Med. 2016; pmid: 26784863 PubMed  
  51. Newton KM, et al. Efficacy of yoga for vasomotor symptoms: A randomized controlled trial. Menopause 2014; 21:339. pmid: 24045673 PubMed  
  52. Cohen LS, et al. Efficacy of omega-3 for vasomotor symptoms treatment: A randomized controlled trial. Menopause 2014; 21:347. pmid: 23982113 PubMed  
  53. Guthrie KA, LaCroix AZ, Ensrud KE, et al. Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms. Obstet Gynecol 2015; 126: 413-22. pmid: 26241433 PubMed  
  54. Sternfeld B et al. Efficacy of exercise for menopausal symptoms: A randomized controlled trial. Menopause 2014; 21:330. pmid: 23899828 PubMed  
  55. Zhu X, Liew Y, Liu ZL. Chinese herbal medicine for menopausal symptoms. Cochrane Database Syst Rev. 2016 Mar 15;3: pmid: 26976671 PubMed  
  56. Franco OH, Chowdhury R, Troup J, et al. Use of Plant-Based Therapies and Menopausal Symptoms: A Systematic Review and Meta-analysis. JAMA. 2016; 315: 2554-63. pmid: 27327802 PubMed  
  57. Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden J, Brown J. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database of Systematic Reviews 2013, Issue 12. Art. No.: CD001395. pmid:24323914 PubMed  
  58. Leach MJ, Moore V. Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database of Systematic Reviews 2012, Issue 9. Art. No.: CD007244. pmid: 22972105 PubMed  
  59. Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015. doi: 10.1001/jamainternmed.2014.8063 DOI  
  60. Honigberg MC, Zekavat SM, Aragam K, et al. Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease. JAMA 2019. doi:10.1001/jama.2019.19191 DOI  
  61. Jean Shin, Kyungdo Han, Jin Hyung Jung et al. Age at menopause and risk of heart failure and atrial fibrillation: a nationwide cohort study, European Heart Journal, 2022;, ehac364, https://doi.org/10.1093/eurheartj/ehac364
  62. Mikkola TS, Tuomikoski P, Lyytinen H, Korhonen P, Hoti F, Vattulainen P, Gissler M, Ylikorkala O. Increased Cardiovascular Mortality Risk in Women Discontinuing Postmenopausal Hormone Therapy. J Clin Endocrinol Metab. 2015 Dec;100(12):4588-94. PMID: 26414962. PubMed  
  63. Socialstyrelsen (2014). Screeningprogram: Bröstcancer, screening med mammografi. www.socialstyrelsen.se  
  • Anna Nager, docent och specialist i allmänmedicin, Karolinska institutet